Exagen (XGN)
(Delayed Data from NSDQ)
$2.40 USD
+0.36 (17.65%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $2.41 +0.01 (0.42%) 4:30 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
XGN 2.40 +0.36(17.65%)
Will XGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XGN
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
XGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for XGN
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript
Exagen GAAP EPS of $0.16 beats by $0.50, revenue of $15.1M beats by $1.97M
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
Exagen reports Q2 EPS (16c), consensus (34c)